Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of Ravidasvir
(ASC16) in combination with Ritonavir-boosted Danoprevir(ASC08) and Ribavirin in
treatment-naive no-cirrhotic Taiwanese patients who have chronic hepatitis C genotype1.